Considering that mirodenafil suppressed canonical TGF-β signaling and TGF-β-mediated expression of COL1A1, α-SMA, and CTGF in our study, we assumed that mirodenafil had potential therapeutic efficacy in the treatment of SSc. The gene discussed is ACTA1; the disease is systemic sclerosis.